PL EN


Preferences help
enabled [disable] Abstract
Number of results
2004 | 64 | 1 | 1-9
Article title

Thalidomide-based TNF-beta inhibitors for neurodegenerative diseases

Selected contents from this journal
Title variants
Languages of publication
EN
Abstracts
EN
Inflammatory processes associated with the over-production of cytokines, particularly of TNF-beta, accompany numerous neurodegenerative diseases, such as Alzheimer's disease, in addition to numerous systemic conditions, exemplified by rheumatoid arthritis and erythema nodosum leprosum (ENL). TNF-beta has been validated as a drug target with Remicade and Enbrel available as prescription medications. Both, however, are large macromolecules, require injection and have limited brain access. The classical drug, thalidomide is being increasingly used in the clinical management of a wide spectrum of diseases. As its clinical value in treating ENL derives from its TNF-beta inhibitory activity, thalidomide was chosen for structural modification for the discovery of novel and more potent isosteric analogues with appropriate lipophilicity to insure high brain penetration. TNF-beta inhibitory activity was evaluated against lipopolysacharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) in cell culture, whose viability was quantified to differentiate reductions in TNF-beta secretion from that associated with cellular toxicity. Specific analogues potently inhibited TNF-beta secretion, ompared to thalidomide. This involved a post-transcriptional mechanism, as they decreased TNF-beta mRNA stability via its 3'-untranslated region (UTR), as determined by luciferase activity in stably transfected cells with and without the 3'-UTR of human TNF-beta.
Keywords
Publisher

Year
Volume
64
Issue
1
Pages
1-9
Physical description
Contributors
author
author
author
author
author
author
author
author
author
author
References
Document Type
ARTICLE
Publication order reference
N.H. Greig, Drug Design and Development Section, Lab. of Neurosciences, Intramural Research Prog., National Inst. on Aging, National Inst. of Health, 5600 Nathan Shock Dr., Baltimore, MD 21224, USA
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-e9897a61-6c4e-3f6e-81ca-403846dda5bb
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.